ATE406916T1 - Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen - Google Patents

Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen

Info

Publication number
ATE406916T1
ATE406916T1 AT02781499T AT02781499T ATE406916T1 AT E406916 T1 ATE406916 T1 AT E406916T1 AT 02781499 T AT02781499 T AT 02781499T AT 02781499 T AT02781499 T AT 02781499T AT E406916 T1 ATE406916 T1 AT E406916T1
Authority
AT
Austria
Prior art keywords
cats
dogs
compositions containing
bacterial infections
treating bacterial
Prior art date
Application number
AT02781499T
Other languages
English (en)
Inventor
Roger Kimball
Renuka Reddy
Evgenyi Shalaev
Simon Blanchflower
Brian Bronk
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE406916T1 publication Critical patent/ATE406916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02781499T 2001-11-30 2002-11-13 Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen ATE406916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33853601P 2001-11-30 2001-11-30
US39893202P 2002-07-26 2002-07-26

Publications (1)

Publication Number Publication Date
ATE406916T1 true ATE406916T1 (de) 2008-09-15

Family

ID=26991236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02781499T ATE406916T1 (de) 2001-11-30 2002-11-13 Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen

Country Status (28)

Country Link
US (1) US7378408B2 (de)
EP (1) EP1448234B1 (de)
JP (1) JP4689959B2 (de)
KR (1) KR100621291B1 (de)
CN (1) CN100502873C (de)
AR (1) AR037595A1 (de)
AT (1) ATE406916T1 (de)
AU (1) AU2002348986B2 (de)
BR (1) BRPI0214583B1 (de)
CA (1) CA2468708C (de)
CY (1) CY1108437T1 (de)
DE (1) DE60228749D1 (de)
DK (1) DK1448234T3 (de)
EA (1) EA008503B1 (de)
ES (1) ES2307800T3 (de)
HK (1) HK1071292A1 (de)
HR (1) HRP20040487A2 (de)
IL (2) IL161851A0 (de)
IS (1) IS7214A (de)
MA (1) MA27085A1 (de)
MX (1) MXPA04003724A (de)
NO (1) NO334818B1 (de)
NZ (1) NZ532208A (de)
PL (1) PL212683B1 (de)
PT (1) PT1448234E (de)
TN (1) TNSN04097A1 (de)
TW (1) TWI248363B (de)
WO (1) WO2003045435A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
CA2563665A1 (en) * 2004-04-22 2005-11-03 Pfizer Products Inc. Method of stabilizing disordered cefovecin sodium salt
EP1656930A1 (de) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilisierte gefriergetrocknete Formulierung für Cephalosporinderivate
KR100900208B1 (ko) * 2004-12-17 2009-06-02 비너스 레머디스 리미티드 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물
NZ555077A (en) * 2005-02-14 2010-03-26 Venus Remedies Ltd Parenteral combination therpy for infective conditions with drug resistant bacterium
US20080318919A1 (en) * 2005-10-29 2008-12-25 Intervet International B.V. Cefquinome Compositions and Methods of Their Use
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8784384B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen compositions and array devices thereof
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
EP3100732A1 (de) * 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Antibiotische ceftolozanzusammensetzungen
EP3319596B1 (de) * 2015-07-09 2023-12-20 Uniwell Laboratories LLC Pharmazeutische zusammensetzungen
US10966929B2 (en) 2015-09-07 2021-04-06 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
TW201920174A (zh) 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
WO2019064065A1 (en) * 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CA3076959A1 (en) 2017-09-27 2019-04-04 Fedora Pharmaceuticals Inc. Crystalline forms of diazabicyclooctane derivatives and production process thereof
GB2575261B (en) 2018-07-02 2022-03-09 Norbrook Lab Ltd Intermediates in the synthesis of C3-substituted cephalosporins
CN109393004A (zh) * 2018-09-28 2019-03-01 上海锦立保鲜科技有限公司 一种利用冻品自由水升华实现真空解冻的方法
WO2023095887A1 (ja) * 2021-11-26 2023-06-01 アステラス製薬株式会社 インドシアニン化合物含有固形医薬組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002748A (en) 1976-01-19 1977-01-11 Eli Lilly And Company Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration
JPS5711909A (en) 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS6045514A (ja) * 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
US5138066A (en) 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
IL89150A0 (en) 1988-02-05 1989-09-10 Lilly Co Eli Crystalline beta-lactam solvate
NO903844L (no) * 1989-09-05 1991-03-06 Neophore Tech Inc Medikamentavgivelsesblandinger basert paa biologiske celler eller komponenter derav og fremgangsmaater.
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
US6020329A (en) 1990-07-24 2000-02-01 Pzifer Inc. Cephaloporins and homologues, preparations and pharmaceutical compositions
US6001997A (en) 1990-07-24 1999-12-14 Bateson; John Hargreaves Cephalosporins and homologues, preparations and pharmaceutical compositions
US5401842A (en) 1992-09-08 1995-03-28 Bristol-Myers Squibb Company Injectable compositions of a cephalosporin dihydrate salt
EP0664117A1 (de) * 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
JP2001199889A (ja) * 1999-11-11 2001-07-24 Takeda Chem Ind Ltd 縮合ピリダジン誘導体を含有してなる点鼻用剤
AU2023401A (en) 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
GB0019124D0 (en) 2000-08-03 2000-09-27 Pfizer Novel process
EP1339722A1 (de) * 2000-12-04 2003-09-03 Pfizer Products Inc. Kupplungsverfahren und zwischenprodukte zur herstellung von cephalosphorinen

Also Published As

Publication number Publication date
TNSN04097A1 (fr) 2006-06-01
JP4689959B2 (ja) 2011-06-01
WO2003045435A1 (en) 2003-06-05
BRPI0214583B1 (pt) 2015-11-17
IL161851A0 (en) 2005-11-20
AU2002348986A1 (en) 2003-06-10
EP1448234B1 (de) 2008-09-03
HRP20040487A2 (en) 2004-10-31
MXPA04003724A (es) 2005-04-08
AR037595A1 (es) 2004-11-17
PL370083A1 (en) 2005-05-16
NZ532208A (en) 2007-01-26
PL212683B1 (pl) 2012-11-30
CN100502873C (zh) 2009-06-24
BR0214583A (pt) 2004-11-03
CA2468708A1 (en) 2003-06-05
KR20040058345A (ko) 2004-07-03
PT1448234E (pt) 2008-10-02
TW200300351A (en) 2003-06-01
ES2307800T3 (es) 2008-12-01
KR100621291B1 (ko) 2006-09-13
US7378408B2 (en) 2008-05-27
NO20042271L (no) 2004-07-22
TWI248363B (en) 2006-02-01
EA200400489A1 (ru) 2004-10-28
MA27085A1 (fr) 2004-12-20
NO334818B1 (no) 2014-06-02
DE60228749D1 (de) 2008-10-16
CN1604793A (zh) 2005-04-06
IS7214A (is) 2004-04-07
EA008503B1 (ru) 2007-06-29
US20030186957A1 (en) 2003-10-02
AU2002348986B2 (en) 2008-04-03
HK1071292A1 (en) 2005-07-15
EP1448234A1 (de) 2004-08-25
JP2005511642A (ja) 2005-04-28
CY1108437T1 (el) 2014-04-09
IL161851A (en) 2011-11-30
CA2468708C (en) 2008-08-19
DK1448234T3 (da) 2008-11-03

Similar Documents

Publication Publication Date Title
ATE406916T1 (de) Cephalosporin verbindungen enthaltende zusammensetzungen und deren verwendung zur behandlung von bakteriellen infektionen bei hunden und katzen
DE60021729D1 (de) Photosensibilisatoren enthaltende antimikrobielle zusammensetzung, gegenstände und verfahren zur verwendung
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
ATE325614T1 (de) Milchsäurebakterienkombination und deren verwendung zur behandlung und prävention von infektionen und entzündungen
ZA200507857B (en) Compositions for treating microbial and parasitic infections in cattle and other animals
DE60113301D1 (de) Gel für die Behandlung von Katzen und Hunden
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE69913520D1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE602005017373D1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
IL169701A0 (en) The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
NO20025204D0 (no) Forbindelser og fremgangsmÕter for behandling og forebygging av bakterielle infeksjoner
ATE337009T1 (de) Medizinische verwendung thyromimetischer verbindungen gegen haarausfall und zusammensetzungen
ATE180944T1 (de) Tuberkilizide synergistische desinfizierende zusammensetzung und verfahren zur desinfektion
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE60112581D1 (de) Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten
ATE539746T1 (de) Zusammensetzung zur verbesserung von kognition und gedächtnis
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60027003D1 (de) Bakterielles konsortium ebc1000 und verfahren zu dessen verwendung zur behandlung von biologisch schwer abbaubaren toxischen chemikalien in industriellem abwasser, abfällen und böden
ATE528004T1 (de) Chinolon-antibiotika zur behandlung von periodontaler infektionen
ATE372132T1 (de) Verfahren zum sterilisieren von gegenständen
DE60011667D1 (de) Verfahren zur erhöhung der reproduzierenden leistung von hunden und katzen
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
GB0519962D0 (en) Composting composition comprising animal urine and agricultural waste and method for vermicomposting the same
ATE372119T1 (de) Verfahren zur behandlung von bakteriellen infektionen mit gemifloxacin oder einem seiner salze und einem beta-lactam-antibiotikum
FR2843539B1 (fr) Dispositif de maintien de pansement pour les membres des chats et des chiens

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1448234

Country of ref document: EP